Stock 6185 CANSINO BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

CanSino Biologics Inc. Stock

Equities

6185

CNE100003F01

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 11:08:15 2024-07-02 pm EDT 		5-day change 1st Jan Change
19.16 HKD +2.13% Intraday chart for CanSino Biologics Inc. -5.05% -18.56%
Jun. 24 Cansino Biologics' Senior Management to Boost Stakeholding MT
Jun. 10 Indonesia ramps up fight against tuberculosis amid concerns on economic impact RE

Financials

Sales 2024 * 860M 118M 924M Sales 2025 * 1.21B 167M 1.3B Capitalization 7.02B 966M 7.54B
Net income 2024 * -286M -39.34M -307M Net income 2025 * 3M 413K 3.22M EV / Sales 2024 * 7.51 x
Net cash position 2024 * 558M 76.77M 600M Net cash position 2025 * 538M 74.04M 578M EV / Sales 2025 * 5.35 x
P/E ratio 2024 *
-14.3 x
P/E ratio 2025 *
-289 x
Employees 1,494
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data

Chart CanSino Biologics Inc.

Dynamic Chart

Latest news about CanSino Biologics Inc.

Cansino Biologics' Senior Management to Boost Stakeholding MT
Indonesia ramps up fight against tuberculosis amid concerns on economic impact RE
CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee CI
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits MT
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine MT
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China CI
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results MT
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug MT
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine CI
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute MT
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine CI
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4% MT
Cansino Biologics Inc. Announces Board and Committee Elections CI
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
More news

Analyst Recommendations on CanSino Biologics Inc.

Cansino Biologics' Senior Management to Boost Stakeholding MT
UBS Adjusts CanSino Biologics' Price Target to HK$88 From HK$200, Keeps at Buy MT
UBS Adjusts CanSino Biologics’ Price Target to HK$200 From HK$202, Keeps at Buy MT
China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up RE
Market Chatter: CanSino's COVID-19 Vaccine Achieves 65.7% Efficacy Rate for Symptomatic Cases MT
More recommendations

Press releases CanSino Biologics Inc.

CanSino Biologics : CanSinoBIO Executives Talk with WHO Experts on the Development Progress of Polio Vaccines PU
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine AQ
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine AQ
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough AQ
CanSino Biologics : CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia PU
More press releases

News in other languages on CanSino Biologics Inc.

AstraZeneca comprará la china Gracell Biotechnologies en una operación de 1.200 millones de dólares
La china CanSino confía en que su vacuna COVID de ARNm sea tan buena como las de Moderna y Pfizer
Début de la migration du Nouvel an lunaire en Chine, hantée par le COVID-19
Cina : consentirà di usare test antigenici per confermare casi Covid-19
ANALYSEN DES TAGES von Dow Jones Newswires (06.12.2022)
More news

Quotes and Performance

1 day+1.39%
1 week-3.06%
Current month-2.66%
1 month-8.56%
3 months+10.07%
6 months-15.84%
Current year-19.24%
More quotes

Highs and lows

1 week
18.70
Extreme 18.7
20.20
1 month
18.70
Extreme 18.7
23.00
Current year
14.80
Extreme 14.8
24.20
1 year
14.80
Extreme 14.8
33.20
3 years
14.80
Extreme 14.8
398.00
5 years
14.80
Extreme 14.8
450.00
10 years
14.80
Extreme 14.8
450.00
More quotes

Managers and Directors - CanSino Biologics Inc.

Managers TitleAgeSince
Hui Hua Mao FOU
 Founder 62 09-01-12
Tao Zhu FOU
 Founder 51 09-01-12
Xue Feng Yu CEO
 Chief Executive Officer 60 09-01-12
Members of the board TitleAgeSince
Shou Bai Chao COO
 Chief Operating Officer 61 18-04-30
Dong Xu Qiu FOU
 Founder 64 09-01-12
Shui Fa Gui BRD
 Director/Board Member 58 19-11-28
More insiders

ETFs positioned on CanSino Biologics Inc.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
0.75% 4 M€ -27.92%
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD ETF KraneShares MSCI China ESG Leaders UCITS ETF Acc - USD
0.11% 2 M€ -1.78% -
ICBCCS S&P CHINA 500 UCITS ETF CLASS B - USD ETF ICBCCS S&P China 500 UCITS ETF Class B - USD
0.01% 35 M€ -5.85% -
More ETFs positioned on CanSino Biologics Inc.

Quotes

Date Price Change Volume
24-07-02 19.16 +2.13% 178 900
24-07-02 18.76 -3.99% 619,585
24-06-28 19.54 +0.72% 360,785
24-06-27 19.4 -3.96% 395,600
24-06-26 20.2 +2.96% 463,200

Delayed Quote Hong Kong S.E., July 02, 2024 at 09:39 pm EDT

More quotes

Company Profile

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Sector
Pharmaceuticals
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for CanSino Biologics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
17.46 CNY
Average target price
25.69 CNY
Spread / Average Target
+47.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CANSINO BIOLOGICS INC. Stock CanSino Biologics Inc.
-19.24% 982M
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+6.58% 39.05B
BIOGEN INC. Stock Biogen Inc.
-11.57% 33.74B
UCB Stock UCB
+79.15% 28.54B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.73% 15.59B
INCYTE CORPORATION Stock Incyte Corporation
-6.00% 13.69B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.55% 11.44B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+166.50% 10.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.80% 9.27B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.19% 9.13B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 6185 Stock